Office of Surveillance and Epidemiology
E392786
The Office of Surveillance and Epidemiology is a U.S. FDA office responsible for monitoring the safety and effectiveness of marketed drugs and therapeutic biologics through post-market surveillance and risk assessment.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Office of Surveillance and Epidemiology canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T3849412 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Office of Surveillance and Epidemiology Context triple: [Center for Drug Evaluation and Research, oversees, Office of Surveillance and Epidemiology]
-
A.
Epidemic Intelligence Service
The Epidemic Intelligence Service is a specialized training and response program that develops disease detectives who investigate and control outbreaks and other public health threats in the United States and abroad.
-
B.
Bureau of Communicable Disease
The Bureau of Communicable Disease is a public health division in New York City responsible for monitoring, investigating, and helping control infectious disease outbreaks.
-
C.
CDC Division of Health Informatics and Surveillance
The CDC Division of Health Informatics and Surveillance is a branch of the U.S. Centers for Disease Control and Prevention that develops and oversees national systems for collecting, analyzing, and sharing public health data to monitor and respond to disease threats.
-
D.
Office of Public Health Preparedness and Response
The Office of Public Health Preparedness and Response is a division of the U.S. Centers for Disease Control and Prevention responsible for coordinating national efforts to prepare for, respond to, and recover from public health emergencies and disasters.
-
E.
Bureau of Environmental Health
The Bureau of Environmental Health is a division of Massachusetts’ state public health agency that focuses on protecting and promoting health by assessing and managing environmental and occupational health risks.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Office of Surveillance and Epidemiology Target entity description: The Office of Surveillance and Epidemiology is a U.S. FDA office responsible for monitoring the safety and effectiveness of marketed drugs and therapeutic biologics through post-market surveillance and risk assessment.
-
A.
Epidemic Intelligence Service
The Epidemic Intelligence Service is a specialized training and response program that develops disease detectives who investigate and control outbreaks and other public health threats in the United States and abroad.
-
B.
Bureau of Communicable Disease
The Bureau of Communicable Disease is a public health division in New York City responsible for monitoring, investigating, and helping control infectious disease outbreaks.
-
C.
CDC Division of Health Informatics and Surveillance
The CDC Division of Health Informatics and Surveillance is a branch of the U.S. Centers for Disease Control and Prevention that develops and oversees national systems for collecting, analyzing, and sharing public health data to monitor and respond to disease threats.
-
D.
Office of Public Health Preparedness and Response
The Office of Public Health Preparedness and Response is a division of the U.S. Centers for Disease Control and Prevention responsible for coordinating national efforts to prepare for, respond to, and recover from public health emergencies and disasters.
-
E.
Bureau of Environmental Health
The Bureau of Environmental Health is a division of Massachusetts’ state public health agency that focuses on protecting and promoting health by assessing and managing environmental and occupational health risks.
- F. None of above. chosen
Statements (41)
| Predicate | Object |
|---|---|
| instanceOf |
FDA office
ⓘ
pharmacovigilance organization ⓘ |
| abbreviation | OSE ⓘ |
| collaboratesWith |
Center for Drug Evaluation and Research
ⓘ
surface form:
Office of New Drugs
other FDA centers ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| field |
drug safety
ⓘ
epidemiology ⓘ pharmacovigilance ⓘ risk management ⓘ |
| goal |
to identify and assess postmarketing safety risks
ⓘ
to monitor effectiveness of marketed drugs ⓘ to monitor safety of marketed drugs ⓘ |
| governmentBranch | executive branch of the United States federal government ⓘ |
| jurisdiction |
Food and Drug Administration
ⓘ
surface form:
United States Food and Drug Administration
|
| language | English ⓘ |
| locatedIn |
Silver Spring, Maryland
ⓘ
United States of America ⓘ
surface form:
United States
|
| parentAgency | Center for Drug Evaluation and Research ⓘ |
| partOf |
Center for Drug Evaluation and Research
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| regulates |
marketed over-the-counter drugs
ⓘ
marketed prescription drugs ⓘ therapeutic biologic products ⓘ |
| responsibleFor |
benefit-risk assessment of approved products
ⓘ
evaluation of adverse drug events ⓘ post-market safety surveillance of drugs ⓘ post-market safety surveillance of therapeutic biologics ⓘ postmarketing requirements and commitments review support ⓘ risk assessment of marketed drugs ⓘ risk assessment of therapeutic biologics ⓘ risk evaluation and mitigation strategies support ⓘ signal detection for drug safety issues ⓘ |
| sector |
public health
ⓘ
regulatory science ⓘ |
| supervisesProcess |
postmarketing pharmacovigilance
ⓘ
risk management planning for drugs ⓘ |
| usesDataSource | FDA Adverse Event Reporting System ⓘ |
| usesMethod |
database analyses
ⓘ
observational epidemiologic studies ⓘ |
| website | https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-surveillance-and-epidemiology ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Office of Surveillance and Epidemiology Description of subject: The Office of Surveillance and Epidemiology is a U.S. FDA office responsible for monitoring the safety and effectiveness of marketed drugs and therapeutic biologics through post-market surveillance and risk assessment.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.